U.S. Hormone Replacement Therapy Market - By Product (Estrogen, Progesterone, Thyroid, Growth Hormone, Testosterone), Route of Administration (Oral, Parenteral), Disease (Menopause, Growth Hormone Deficiency), Distribution Channel, Forecast 2023-2032

Description

List of Tables

U.S. hormone replacement therapy market size is projected to expand at 6.5% CAGR from 2023 to 2032. The aging population, particularly among baby boomers, is increasing the prevalence of hormonal imbalances and age-related conditions, fueling the demand for hormone replacement therapies (HRTs) in the country.

The rising advancements in hormone therapies is leading to the growing awareness of the benefits of HRT in managing menopausal symptoms and age-related disorders. For instance, in June 2023, Pfizer Inc. and OPKO Health Inc. announced FDA approval for NGENLA (somatrogon-ghla), a weekly human growth hormone analog, indicated for treating growth failure in pediatric patients aged 3 years and older due to insufficient secretion of endogenous growth hormone. Furthermore, the ongoing R&D activities for innovative hormone replacement formulations and delivery methods is making way for enhanced treatment options. Additionally, the changing lifestyles, rising healthcare expenditure, and the proactive approach to women health in the U.S. will drive the market growth.

The U.S. hormone replacement therapy industry is segregated into product, route of administration, disease type, and distribution channel.

Based on product, the industry value from the growth hormone replacement therapy segment is projected to rise at 6.9% CAGR through 2032. This is owing to the increasing awareness and diagnosis of growth hormone deficiencies in the region. The higher advancements in therapeutic formulations, and the rising demand for effective treatments among pediatric patients with growth disorders will also drive the segment growth ahead.

U.S. hormone replacement therapy market share from the hypothyroidism disease type segment is estimated to witness 5.6% CAGR from 2023 to 2032, due to the rising incidence of thyroid disorders and the growing awareness for early diagnosis. The increasing advancements in hormone replacement formulations and the surging patient preference for effective hypothyroidism management will also boost the segment growth.

The market value from the parenteral route of administration segment is anticipated to register 7% CAGR through 2032. The growth can be attributed to the increasing preference for direct and controlled delivery of hormones, rapid onset of action, and improved treatment compliance. Patient convenience coupled with higher advancements in parenteral administration technologies will also fuel the adoption of parenteral administration for HRTs in the country.

Product Code: 7407

Chapter 1 Methodology & Scope

1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast calculation
1.4 Covid-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 U.S. hormone replacement therapy industry 360 degree synopsis, 2018 - 2032 (USD Million)
- 2.1.1 Business trends

Chapter 3 U.S. Hormone Replacement Therapy Market Insights

3.1 Industry landscape, 2018 - 2032 (USD Million)
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing geriatric population
  - 3.2.1.2 Rising awareness of post-menopausal issues
  - 3.2.1.3 Increasing development of novel drug delivery systems for hormone imbalance issues
  - 3.2.1.4 Rising prevalence of hormonal disorders
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost associated with hormone replacement therapy
  - 3.2.2.2 Adverse effects of hormone replacement therapy
3.3 Growth potential analysis
- 3.3.1 By product
- 3.3.2 By route of administration
- 3.3.3 By disease type
- 3.3.4 By distribution channel
3.4 COVID-19 impact analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategic dashboard, 2022

Chapter 5 U.S. Hormone Replacement Therapy Market Estimates and Forecast, By Product, 2018 - 2032 (USD Million)

5.1 Key trends, by product
5.2 Estrogen & progesterone replacement therapy
5.3 Thyroid replacement therapy
5.4 Growth hormone replacement therapy
5.5 Parathyroid hormone replacement therapy
5.6 Testosterone replacement therapy

Chapter 6 U.S. Hormone Replacement Therapy Market Estimates and Forecast, By Route of Administration, 2018 - 2032 (USD Million)

6.1 Key trends, by route of administration
6.2 Oral
6.3 Parenteral
6.4 Other routes of administration

Chapter 7 U.S. Hormone Replacement Therapy Market Estimates and Forecast, By Disease Type, 2018 - 2032 (USD Million)

7.1 Key trends, by disease type
7.2 Menopause
7.3 Growth hormone deficiency
7.4 Male hypogonadism
7.5 Hypothyroidism
7.6 Hypoparathyroidism
7.7 Other disease types

Chapter 8 U.S. Hormone Replacement Therapy Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 (USD Million)

8.1 Key trends, by distribution channel
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies

Chapter 9 Company Profiles

9.1 Eli Lilly and Company
9.2 Bayer AG
9.3 Pfizer Inc.
9.4 Viatris, Inc.
9.5 Noven Pharmaceuticals, Inc.
9.6 Merck KGaA
9.7 Novo Nordisk A/S
9.8 F. Hoffmann-La Roche Ltd.
9.9 ASCEND Therapeutics US, LLC.
9.10 Abbott Laboratories
9.11 Teva Pharmaceutical Industries Ltd.
9.12 Novartis AG